Upload File

center for drug evaluation and research · determination of equilibrium binding constants for the...

  • Home
  • Documents
  • CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
82
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125387Orig1s000 PHARMACOLOGY REVIEW(S)

Upload: others

Post on 29-Mar-2020

13 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

125387Orig1s000

PHARMACOLOGY REVIEW(S)

Page 2: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 3: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 4: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 5: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 6: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 7: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 8: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 9: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 10: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 11: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 12: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 13: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 14: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 15: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 16: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 17: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 18: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 19: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 20: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 21: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 22: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 23: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 24: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 25: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 26: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 27: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 28: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 29: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 30: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 31: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 32: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 33: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 34: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 35: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 36: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 37: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 38: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 39: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 40: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 41: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 42: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 43: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 44: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 45: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 46: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 47: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 48: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 49: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 50: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 51: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 52: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 53: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 54: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 55: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 56: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 57: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 58: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 59: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 60: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 61: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 62: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 63: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 64: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 65: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 66: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 67: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 68: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 69: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 70: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 71: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 72: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 73: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 74: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 75: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 76: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 77: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 78: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 79: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 80: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 81: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and
Page 82: CENTER FOR DRUG EVALUATION AND RESEARCH · Determination of Equilibrium Binding Constants for the Interaction of Human VEGF-A165 and Human PIGF-2 with Aflibercept Conformance and

Department of Ophthalmology University of Padova Edoardo Midena Clinica Oculistica Università di Padova Aflibercept & Wet AMD

Aflibercept for treating myopic choroidal neovascularisation

ID-A165 38 AIRCRAFT PERFORMANCE OPTIMIZATION WITH THRUST ... · PDF fileid-a165 38 aircraft performance optimization with thrust vector 1/2 38 control(u) air force inst of tech mright-patterson

Case Report Intravitreal Aflibercept Injection and ...2019-7-31 · Case Report Intravitreal Aflibercept Injection and ... a single session of photodynamic therapy. 2. Report of

Intravitreal Aflibercept as a Rescue Therapy for Retinal ...Case Report Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease

Aflibercept: a Potent Vascular Endothelial Growth Factor ...Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases ... Treatment of

320 J.G.Whittaker - Hydrologie.orghydrologie.org/redbooks/a165/iahs_165_0319.pdf320 J.G.Whittaker 8 angle of bed between end of scour hole and next step downstream, relative to horizontal

PRODUCT INFORMATION EYLEA aflibercept (rch) NAME …bayerresources.com.au/resources/uploads/PI/file10294.… ·  · 2017-11-23PRODUCT INFORMATION EYLEA ® aflibercept (rch) NAME

FFCD 1302 EFFICACY AND SAFETY OF AFLIBERCEPT IN

Efficacy of intravitreal AFlibercept injection For

EYLEA (aflibercept) Injection For Intravitreal …® (aflibercept) Injection For Intravitreal Injection ... Diabetic Macular Edema (DME) ... injection needle onto the Luer lock syringe

Eylea® (aflibercept) Injectable Medication ... · 503 Sunport Lane, Orlando, FL ... Please indicate the patient’s BCVA prior to initiating ... (aflibercept) Injectable Medication

Australian Public Assessment Report for Aflibercept · This AusPAR describes the application by the sponsor, Bayer Australia Ltd, to extend the indications for Eylea ( aflibercept)

PRE-ECLAMPSIA SCREENING WTHI PIGF 1-2-3 KIT...pre-eclampsia is also associated with preterm birth and fetal growth restriction, with prematurity accounting for most pre-eclampsia-related

One-year outcomes of fixed-dosing Aflibercept therapy for

Aflibercept exhibits VEGF binding stoichiometry …...Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

1 Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV

Australian Public Assessment Report for Aflibercept …...management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety

Retinal metabolic and structural alterations in response to … · Retinal metabolic and structural alterations in response to aflibercept treatment in neovascular age‐ related

Effect of intravitreal injection of aflibercept or ... · RETINAL DISORDERS Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal

Efficacy and safety of brolucizumab versus aflibercept in

Australian public assessment report for Aflibercept … · Web viewAdministration of aflibercept SC on days 13, 16 and 19 post-implantation at doses of 1040 mg/kg (but not ≤2.5

Switch to Aflibercept in the Treatment of Neovascular AMD ...downloads.hindawi.com/journals/joph/2017/6835782.pdfResearch Article Switch to Aflibercept in the Treatment of Neovascular

AusPAR Attachment 1. Product Information for Aflibercept€¦  · Web viewAttachment 1: Product information for AusPAR Eylea Aflibercept Bayer Australia Ltd PM-2013-04198-1-1 Final

R. M. IVERSON & R. P. DENLINGERhydrologie.org/redbooks/a165/iahs_165_0155.pdf · 156 R.M.Iverson & R.P.Denlinger of debris flows makes their dynamics difficult to conceptualize and

Berg Rivier IWMP update - fewlbnexus.uct.ac.za · -i- Y:\Projdata\A165\Berg_Rivier_IWMP_update.doc\jm IWMP Bergrivier : Draft BERGRIVIER MUNICIPALITY INTEGRATED WASTE MANAGEMENT PLAN

RUTH VERA ONCOLOGÍA MÉDICA CHN Madrid, 12 de Febrero de 2015 ENCAJE CLÍNICO DE AFLIBERCEPT EN EL CONTEXTO ACTUAL DEL CCRM

Accountability and Performance Measurement: A Stakeholder Perspective › a165 › 34a7f2273106959610... · 2017-09-28 · Accountability and Performance Measurement: A Stakeholder

Erosion and Sedimentation in the Pacific Rim - …hydrologie.org/redbooks/a165/iahs_165_0287.pdfErosion and Sedimentation in the Pacific Rim ... channels is the great range in time

AD-A165 421 QUANTIFICATION OF TECHNICAL MANUAL …i ad-a165 421 quantification of technical manual graphics i comprehensibiliti(u) navy personnel research and i development center

PowerPoint Presentation · Green Fluorescent Protein • ß Galactosidase Lucia Gaussia , hTNFR-Is .hTNFR-Is/mIgG1 Lenercept EYS606 S-FIt1 'Aflibercept • EYS609 .CNTF .GDNF •

Aflibercept and Ranibizumab Modulate Retinal …...Prof. Elena Grossini Laboratory of Physiology and Experimental Surgery, Department of Translational Medicine University of Eastern

Supplementary Material - Springer Static Content Server10.1007/s123…  · Web viewBerg K, Pedersen TR, Sandvik L, ... bevacizumab altuzan eylea aflibercept trap-eye trapeye zaltrap

Intravitreal Aflibercept Injection for Macular Edema

125418Orig1s000 - Food and Drug Administration€¦ · APPLICANT: Sanofi-aventis U.S. Inc. PRODUCT: Intravenous Aflibercept INDICATION Treatment of patients with metastatic colorectal